Vertex Pharma stock gains analyst support as JPMorgan raises price target

Published on 09/11/2026 at 16:56 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Vertex Pharma stock trades around USD 517 on Nasdaq as of September 11, 2026, after JPMorgan lifted its price target to USD 560 and reaffirmed an Overweight rating. Recent quarterly revenue of USD 3.33 billion marked 12.5 percent year on year growth, modestly ahead of expectations.

Bauhaus-Poster mit geometrischen Formen, Molekülsymbol und großem Schriftzug PHARMA — Vertex Pharma US92532F1003 zeigt ein geometrisches Bauhaus-Poster mit Sektor-Text PHARMA und stilisierter Molekülgrafik, Illustration mit AI erstellt.

Vertex Pharmaceuticals Inc. (ISIN US92532F1003) stock is trading around USD 517 on Nasdaq on September 11, 2026, after JPMorgan resumed coverage with an Overweight rating and raised its price target to USD 560 from USD 515, implying upside of almost 9 percent to the latest closing price.

JPMorgan lifts target and resumes coverage

According to GuruFocus on September 11, 2026, JPMorgan resumed coverage of Vertex Pharmaceuticals with an Overweight rating and increased its price target to USD 560 from USD 515, highlighting the company’s strategic expansion and recent acquisition activity as support for long term growth.

As Dow Jones Newswires reported on September 11, 2026, the new USD 560 target reflects JPMorgan’s view that Vertex’s pipeline and diversification efforts can sustain double digit revenue growth while supporting margin resilience.

Strong recent revenue growth versus expectations

Vertex’s most recent quarterly report gives investors more context for the analyst optimism. According to Yahoo Finance, in its second quarter of fiscal 2026 Vertex generated revenue of USD 3.33 billion, an increase of 12.5 percent year on year, which exceeded analysts’ expectations by 4.6 percent and led management to guide full year revenue slightly above consensus.

In the same analysis, the stock was noted trading around USD 521.32 shortly after the Q2 release, up 10.8 percent since the report, indicating that the market had already rewarded the company for the combination of double digit top line growth and guidance that came in ahead of expectations.

Valuation, consensus targets and upcoming earnings date

Vertex’s valuation and broader analyst consensus frame the JPMorgan move. As MarketBeat summarized on September 11, 2026, Vertex shares opened at USD 514.56, and the stock carries a consensus rating of Moderate Buy with an average analyst price target of around USD 570.83, while Royal Bank of Canada recently raised its own target from USD 543 to USD 570 and kept an Outperform rating.

Looking ahead, earnings calendars indicate that Vertex Pharmaceuticals is scheduled to report its third quarter 2026 results on November 9, 2026, a date already flagged in analyst material as a key checkpoint for revenue trends and margin development, as noted in a recent overview cited by syndicated corporate news.

Stock level and recent performance

Per Nasdaq data reflected in a Barron’s research and ratings snapshot, Vertex Pharmaceuticals stock closed at USD 514.56 on Nasdaq on September 10, 2026, down USD 6.56 or 1.26 percent on the day, with before hours indications at USD 517.48 on September 11, 2026, and a prior close referenced at USD 514.56, placing the shares modestly below the recent level highlighted by JPMorgan’s target and near term upside projection.